TARC Identifies Poor Dupilumab Response in Atopic Dermatitis TARC Identifies Poor Dupilumab Response in Atopic Dermatitis

Serum thymus and activation-regulated chemokine (TARC) levels may pinpoint a category of atopic dermatitis cases needing the most intensive dupilumab treatment.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news